Phase I/IIa, Single-Arm, Open Study of Apatinib and MASCT in Patients With Advanced Solid Tumors
Latest Information Update: 20 Jan 2020
At a glance
- Drugs Dendritic cell vaccines (Primary) ; Rivoceranib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 31 May 2019 Results of pooled analysis of two prospective trials (NCT02844881; NCT02858232) assess the toxicity and efficacy of PD-1 blockade (SHR-1210)-activated MASCT (aMASCT) alone or in combination with apatinib published in conjunction with the 55th Annual Meeting of the American Society of Clinical Oncology
- 28 Jul 2016 New trial record